What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The TITAN trial demonstrated that apalutamide plus ADT significantly increases radiographic progression-free survival compared to placebo plus ADT, with a hazard ratio of 0.5. However, there is no direct evidence comparing apalutamide plus ADT with ADT alone for patients who cannot have docetaxel, which introduces uncertainty regarding its effectiveness in this subgroup.
Does the economic case hold at the expected price? — Cost effectiveness
Apalutamide plus ADT is not cost-effective compared to docetaxel, with cost-effectiveness estimates well above the acceptable range for Healthcare resources. However, it is considered acceptable compared to ADT alone for patients who cannot have docetaxel, indicating some marginal cost-effectiveness in this specific context.
Is there quality-of-life evidence payers weigh? — Quality of life
The mean change in EQ-5D-5L scores showed no significant difference between apalutamide plus ADT and placebo plus ADT, indicating no demonstrated improvement in quality of life. The lack of significant findings suggests that while apalutamide may be tolerated, it does not provide a clear benefit in HRQoL compared to standard care.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Apalutamide plus ADT has a well-tolerated safety profile, with manageable adverse effects such as rash and hypothyroidism. The committee concluded that these adverse effects do not significantly undermine the treatment’s overall value.
Was the drug compared against what payers expect? — Comparator Selection
The primary comparison in the TITAN trial was against placebo plus ADT, which is appropriate. However, there is a lack of direct evidence comparing apalutamide plus ADT with docetaxel plus ADT, which limits the robustness of the evidence regarding its comparative effectiveness.
Is the population defined the way payers need it? — Patient Population and Subgroups
The TITAN trial population included patients with ECOG scores of 0, 1, or 2, which reflects a reasonable representation of the intended patient population. However, the exclusion of patients who cannot have docetaxel raises concerns about the generalizability of the findings to this subgroup.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Apalutamide can be integrated into existing treatment pathways with minimal disruption, as it is an oral treatment that requires less monitoring than docetaxel. This facilitates its adoption in clinical practice.
Are the wider system costs understood? — Resource Use and Cost Implications
While the cost of apalutamide is high, the company has provided a discount arrangement, making it more manageable within the Healthcare budget. However, the overall resource implications remain a concern due to the high costs associated with its use.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence from the TITAN trial is robust, being a phase 3 randomized controlled trial. However, the lack of direct evidence for the subgroup of patients who cannot have docetaxel introduces some limitations in the overall evidence quality.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding the cost-effectiveness of apalutamide for patients who cannot have docetaxel, as the evidence base for this subgroup is lacking. This uncertainty may restrict its use in practice.
